ATIM-16. VALIDATION OF RESPONSE TO NEOADJUVANT ANTI-PD-1 IMMUNOTHERAPY IN RECURRENT GLIOBLASTOMA

BACKGROUND: Recurrent glioblastoma has a poor median overall survival despite multimodal treatment. The use of pembrolizumab, an anti-PD-1 monoclonal antibody, demonstrates promise, including improved overall survival and increased immune response, when used in the neoadjuvant setting. METHODS: We e...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Main Authors: Chow, Frances, Mochizuki, Aaron, Lee, Alexander, Galvez, Mildred, Orpilla, Joey, Everson, Richard, Liau, Linda, Cloughesy, Timothy, Prins, Robert
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2019
Assuntos:
Adult Clinical Trials–Immunologic
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847707/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.016
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares